Does Stem Cell Therapy Help With Arthritis?

Stem cell therapy can modestly reduce arthritis pain and improve joint function in the short term, but the benefit is smaller than most clinic advertisements suggest, and a surprisingly large share of the improvement may come from placebo-like effects. A 2024 Cochrane review of placebo-controlled trials for knee osteoarthritis found that stem cell injections improved pain by roughly 1.2 points on a 10-point scale compared to sham injections, with similarly modest gains in function. That is a real, if limited, signal buried under a mountain of hype, and the picture gets more complicated the closer you look.

What the Strongest Evidence Actually Shows

The most reliable snapshot comes from the Cochrane systematic review published in 2024, which pooled data from seven placebo-controlled trials involving 445 patients with knee osteoarthritis. Average pain in the placebo groups sat at about 4.5 out of 10, while the stem-cell groups scored about 1.2 points lower. For function, measured on a 0-to-100 scale, stem cell recipients improved roughly 14 points more than placebo recipients. The review’s authors rated the certainty of evidence as low, partly because results varied widely across individual studies.¹

Those numbers are worth pausing on. A 1.2-point drop on a 10-point pain scale sounds clinically meaningful if you squint, but it sits at the edge of what patients typically perceive as a genuine difference. And the wide confidence intervals in the review (ranging from 2.5 points better to essentially zero benefit) mean some patients might get meaningful relief while others get none at all.

Separate meta-analyses of randomized controlled trials have broadly agreed that stem cell injections outperform controls on pain and function scores, with subgroup analyses suggesting that adipose-derived cells and higher doses tend to show stronger effects.² But individual high-quality trials have sometimes failed to separate stem cells from placebo. The ADIPOA2 phase 2b trial, one of the larger and more rigorous tests of adipose-derived stem cells, found that roughly 47% of patients in the stem-cell group met strict response criteria at six months compared to about 55% in the placebo group, a difference that was not statistically significant.³

How Much Is Placebo?

One of the most uncomfortable findings in this field is how much of the observed improvement traces back to what researchers call contextual factors: the injection ritual, patient expectations, the therapeutic encounter. A 2025 systematic review and meta-analysis specifically measured this and found that at six months, contextual factors accounted for about 63% of the total pain reduction and 61% of the functional improvement seen in stem-cell trials. At twelve months, contextual factors still explained roughly half the pain relief and about two-thirds of the functional gains.⁴

This does not mean the treatment is entirely a sham. Placebo effects are real physiological responses, and the remaining portion of benefit could reflect genuine biological activity. But it does mean that if a clinic shows you testimonials from thrilled patients who received stem cell injections without any control group comparison, you are mostly seeing the placebo response at work. The biological contribution of the cells themselves is modest by comparison, at least with current delivery methods and dosing.

Cell Source, Dose, and Preparation Matter

Not all stem cell injections are the same product. The cells can come from your own bone marrow, your own fat tissue, umbilical cord tissue from a donor, or other sources. How they are processed also varies: some clinics inject a crude concentrate taken straight from your tissue (called stromal vascular fraction or bone marrow aspirate concentrate), while others culture and expand the cells in a lab before injecting a defined dose.

A 2025 network meta-analysis compared different cell sources and doses across randomized trials and found that adipose-derived stem cells at moderate doses ranked highest for long-term improvements in joint pain and function scores. Bone marrow-derived cells at low doses also outperformed controls but showed smaller effects.⁵ A separate meta-analysis focused on adipose-derived cells found that high-dose injections (above 50 million cells) produced the best early improvements in pain and dysfunction, but came with more side effects.⁶

An animal study comparing stromal vascular fraction against purified adipose-derived stem cells found essentially similar cartilage regeneration and anti-inflammatory effects from both preparations, even though the purified group received a much higher concentration of actual stem cells. That suggests other cell types in the crude mixture may contribute to the therapeutic effect or that you do not need a perfectly pure population to get results.⁷ This is an active area of investigation, with at least one large randomized trial now underway comparing bone marrow concentrate against fat-derived concentrate head-to-head in 204 patients with knee osteoarthritis.⁸

Who Is Most Likely to Benefit

The general pattern across studies is that patients with mild-to-moderate osteoarthritis tend to respond better than those with severe joint damage. If your knee is already bone-on-bone with little cartilage remaining, an injection of stem cells has very limited raw material to work with. The cells appear to reduce inflammation and may slow further cartilage loss, but they are not rebuilding a joint from scratch. For advanced disease, joint replacement remains the more reliable option.

One umbrella analysis comparing outcomes between stem cell therapy and total knee replacement found that patients who received stem cells had a lower rate of eventually needing a knee replacement over three to five years: about 12% compared to roughly 23% in control groups. That suggests stem cell therapy could delay surgery for some patients, particularly those who are not yet candidates for a full replacement or want to postpone one.

Age and overall health also appear to play a role, though the data are thinner. Younger patients with sports injuries or early degenerative changes seem to form the theoretical sweet spot, but rigorous evidence specifically comparing age groups within randomized trials is limited. Most trials have enrolled patients between 40 and 75, which makes it hard to isolate age as a factor.

The Safety Profile

On the safety side, the news is fairly reassuring in the short term. A 2024 systematic review covering nearly 2,000 patients who received stem cell injections for knee osteoarthritis found an overall rate of transient side effects of about 12%, mostly swelling and pain around the injection site that resolved within a few weeks. No serious adverse events such as infections, blood clots, tumors, or deaths were reported.⁹

The type of cells used influenced side-effect rates considerably. Umbilical cord-derived cells had the highest rate of transient adverse events (about 52%), followed by cultured adipose-derived cells (about 30%), while bone marrow-derived cells and stromal vascular fraction injections caused fewer short-term complaints.⁹ The higher-dose preparations that showed better efficacy in meta-analyses also tended to produce more side effects, consistent with a dose-response pattern on both the benefit and harm side.⁶

Long-term safety data beyond a year or two remain scarce. Most trials have followed patients for six to twelve months. Whether repeated injections carry cumulative risks is an open question.

What About Rheumatoid Arthritis?

The discussion so far has centered on osteoarthritis, which involves mechanical wear and degeneration of cartilage. Rheumatoid arthritis is a fundamentally different disease driven by the immune system attacking the joint lining. Stem cells are of interest here not for their cartilage-building potential but for their ability to dampen an overactive immune response.

Mesenchymal stem cells have immunomodulatory properties: they can dial down inflammatory signaling and shift the balance of immune cells toward a less aggressive state.¹⁰ Both experimental studies and early-stage clinical trials have shown that these cells can reduce markers of inflammation in rheumatoid arthritis.¹¹ But the clinical evidence here is even thinner than for osteoarthritis. There are no large, placebo-controlled trials establishing clear benefit in RA patients the way there are (however modestly) for knee OA. The field is still in early translational stages, and existing biologic drugs for RA are already quite effective, setting a high bar for any new therapy to clear.

The Direct-to-Consumer Problem

If you have searched for stem cell therapy online, you have probably encountered dozens of clinics offering injections for arthritis, often with enthusiastic language about “regeneration,” “healing,” and “avoiding surgery.” The commercial landscape for stem cell treatments has grown rapidly, and much of it operates in a regulatory gray zone.

A study published in Cell Stem Cell documented widespread marketing of unapproved stem cell interventions by businesses in the United States, despite the fact that most of these treatments have not undergone the rigorous clinical trials required for FDA approval.¹² Many clinics use autologous preparations (cells from your own body), which they argue exempts them from certain regulations. The FDA has pushed back on this interpretation in some cases but enforcement has been inconsistent.

Insurance coverage reflects the same uncertainty. In India, where at least one allogeneic stem cell product has received regulatory approval for knee osteoarthritis, insurers still commonly classify the treatment as experimental and decline to cover it.¹³ In the United States, out-of-pocket costs for stem cell injections typically run several thousand dollars per treatment, and you should expect no insurance reimbursement. That price tag makes the modest and uncertain benefits harder to justify, especially when cheaper alternatives like physical therapy, weight management, and corticosteroid or hyaluronic acid injections can also produce meaningful symptom relief.

Exosomes and the Next Generation of Approaches

Researchers are increasingly interested in whether you even need to inject whole cells. Stem cells release tiny membrane-bound packages called exosomes that carry signaling molecules, and some evidence suggests these packages alone can reduce inflammation, promote cartilage repair, and slow the breakdown of joint tissue.¹⁴¹⁵ The appeal is practical: exosomes are easier to standardize, store, and ship than living cells, and they may avoid some of the variability that plagues current stem cell treatments. Nearly all the evidence here comes from lab and animal work, though, so exosome-based therapies for arthritis in humans are still years from any definitive clinical data.

Another frontier is combining stem cells with engineered scaffolds. In animal models, researchers have seeded stem cells onto biodegradable structures designed to fit into cartilage defects. One approach used fibrous scaffolds loaded with a growth factor called BMP-7 alongside synovium-derived stem cells in rabbits, producing thick hyaline cartilage at the defect site.¹⁶ Others have used 3D-printed scaffolds that mimic the layered structure of natural cartilage and bone, showing encouraging cell survival and cartilage-like tissue formation in lab settings.¹⁷ These scaffold-based strategies aim to solve a fundamental limitation of simple injections: injected cells tend to disperse and die quickly rather than staying put in the damaged area. But translating rabbit-scale cartilage patches to weight-bearing human joints is a significant engineering challenge.

Lessons From Veterinary Medicine

Stem cell therapy for arthritis has actually seen broader clinical use in dogs than in humans, partly because veterinary regulation is less restrictive and partly because large-breed dogs develop osteoarthritis at high rates. These studies offer a useful parallel, though not a direct prediction of human outcomes.

A systematic review of veterinary evidence found moderate support for stem cell injections reducing pain and lameness in dogs with osteoarthritis compared to placebo, based on both owner assessments and veterinary evaluations.¹⁸ One double-blinded placebo-controlled trial in dogs with chronic elbow osteoarthritis reported treatment success in about 50% of stem-cell recipients versus 27% of placebo recipients at three months, with the gap widening further by six months (46% versus 14%). No adverse effects from the cells were noted.¹⁹

The dog data are encouraging in that they show a real biological effect in a species that does not respond to marketing promises or bedside manner, which partly addresses the placebo question that haunts human trials. At the same time, dogs are not people, and the fact that veterinary and human results do not always line up in other fields of medicine means these findings are suggestive rather than conclusive for clinical decisions about your own joints.